Bibliography
- Dorsey ER, Constantinescu R, Thompson JP, Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384-6
- Tanner CM, Goldman SM. Epidemiology of Parkinson's disease. Neurol Clin 1996;14:317-35
- Van Den Eeden SK, Tanner CM, Bernstein AL, Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003;157:1015-22
- Huse DM, Schulman K, Orsini L, Burden of illness in Parkinson's disease. Mov Disord 2005;20:1449-54
- Olanow CW, Rascol O, Hauser R, A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361:1268-78
- Mori A, Shindou T. Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists. Neurology 2003;61:S44-8
- Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 2001;24:31-55
- Schiffmann SN, Fisone G, Moresco R, Adenosine A2A receptors and basal ganglia physiology. Prog Neurobiol 2007;83:277-92
- Calon F, Dridi M, Hornykiewicz O, Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 2004;127:1075-84
- Kanda T, Jackson MJ, Smith LA, Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998;43:507-13
- Grondin R, Bedard PJ, Hadj Tahar A, Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 1999;52:1673-7
- Kanda T, Jackson MJ, Smith LA, Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 2000;162:321-7
- Bibbiani F, Oh JD, Petzer JP, A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp Neurol 2003;184:285-94
- Aoyama S, Kase H, Borrelli E. Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J Neurosci 2000;20:5848-52
- Bara-Jimenez W, Sherzai A, Dimitrova T, Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 2003;61:293-6
- Hauser RA, Hubble JP, Truong DD. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 2003;61:297-303
- Stacy M, Silver D, Mendis T, A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 2008;70:2233-40
- LeWitt PA, Guttman M, Tetrud JW, Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 2008;63:295-302
- Hauser RA, Shulman LM, Trugman JM, Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord 2008;23:2177-85
- Mizuno Y, Hasegawa K, Kondo T, Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. Mov Disord 2010;25:1437-43
- Guttman M. Efficacy of istradefylline in Parkinson's disease patients treated with levodopa with motor response complications: primary efficacy results of the KW-6002 US-018 study. Mov Disord 2006;21(Suppl 15):S585
- Fernandez HH, Greeley DR, Zweig RM, Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. Parkinsonism Relat Disord 2010;16:16-20
- Factor S, Mark MH, Watts R, A long-term study of istradefylline in subjects with fluctuating Parkinson's disease. Parkinsonism Relat Disord 2010;16:423-6